Introduction: Optimal post-remission treatment for acute myeloid leukemia patients with
normal karyotype (AMLNK) in first complete remission (CR1) who lacks an HLA identical …

Introduction: Post-remission therapy in acute myeloid leukemia (AML) is mainly guided by
cytogenetic and molecular risks, patient age and performance status. Favorable AML is …

A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving
autologous blood stem cell transplantation (ABSCT) were investigated in order to determine …

Thanks to the recent developments in transplant procedures, an increasing number of
patients with acute myeloid leukemia (AML) with a poor Karnofsky Performance Status …

In patients with acute myeloid leukemia (AML) of intermediate-risk (IR) in first remission
(CR1) with no measurable residual disease (MRD negative), the choice of the best …

Abstract 4129 In patients with cytogenetically normal AML, the mutational status of FLT3,
NPM1 and CEBPA are associated with the outcome (Schlenk, NEJM 2008). In that study, the …

The prognosis of patients with refractory/relapsed acute myelogenous leukemia (rAML) is
poor. Recent studies have shown that more transplant centers are choosing allogeneic …

Background For favorable-and intermediate-risk AML patients who lack of an available HLA-
matched donor, the post-remission treatment is controversial. Autologous stem cell …

To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …

Background: The preferred type of postremission therapy (PRT) for intermediate-risk acute
myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate …